Determinants of outcome in melanoma patients with cerebral metastases.
about
Melanoma brain metastases: an unmet challenge in the era of active therapyThe pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapyMelanoma Brain Metastasis: Mechanisms, Models, and MedicineBRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapySystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.Primary malignant melanoma in the pineal region treated without chemotherapyMulticenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandPrimary melanoma of the cervical spine with cerebral metastases: case report and review of the literature.First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.[Melanoma brain metastases : Treatment options].Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival.Treatment options for limited or symptomatic metastatic melanoma.Prognostic indices for brain metastases--usefulness and challengesEfficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesDeterminants of survival in patients with brain metastases from cutaneous melanoma.Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasibleFactors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastasesDifferential effects of radiation and age on diffusion tensor imaging in rats.DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterationsEfficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanomaMolecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic targetSurgery for distant melanoma metastasis.Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.Surgical management of melanoma brain metastases in patients treated with immunotherapy.Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survivalRadiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma.A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.Stereotactic radiosurgery for brain metastases from malignant melanomaTreatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral siteImpact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelA miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.An uncommon presentation and course of metastatic malignant melanoma: a case report.Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.Melanoma brain metastases and vemurafenib: need for further investigation.
P2860
Q26995622-8F0C4389-0FAE-4BC9-AFF0-373B32C5D95EQ27004672-144983F9-4637-405E-A175-CC1057F9A161Q28069421-02904079-FA92-4717-A004-2BAD1A618031Q28076667-49731ADD-9F7D-421B-8832-5BAD3D620756Q30239901-08884A4D-85DC-44B1-9A5F-12FDE0626FE1Q30251581-963EC17D-6A6F-4F2D-A248-146111EC96FCQ30460114-626AAB58-EBB3-4BE4-932E-9FDBAEE35446Q30491702-0DD7FEF6-7F78-437F-931A-DCEA0F6CF846Q30558419-A1A0B054-EC00-4B3D-AEE7-C86B73B05CE8Q30946452-647BF771-02A8-4D03-B6C7-3B043A6EFC53Q31098294-F9E312C4-FBF6-4C59-BBCF-94CFDE907276Q31141368-503F7FE4-050B-4A0B-9975-C21460D9659DQ31161199-BC050D99-BF3A-49E2-AB7F-CE9CCA18FC88Q33414874-2A125858-C8FD-4B57-910D-A1A52359DB12Q33620317-9E02CE57-AADE-408A-A3FD-1797034BB4D5Q33794890-1ACD5BBB-64B1-4E69-BE11-B196FB1DD017Q33851421-F51148C5-64B2-470B-AE3E-51DD7200A211Q33942964-07E66344-A140-41E4-90F5-BE16D9CF6942Q34108267-B1EB04BD-F31D-4302-8339-06406F6802F5Q34359695-FA08D798-9ED3-4D3F-A80B-5B1DDC310E63Q34362809-ABA4EB5B-2000-40BB-BC13-273E22F301B8Q34438536-AF52827F-E269-4443-BDBE-5CD319D0075DQ34636992-245F6FBF-A5A0-429E-8743-B18C2E8BEDDDQ34641609-4875C8C1-03D0-44D8-A86F-174A37279930Q34954990-42CB1E28-FA52-4F92-8C9D-020C13E5D045Q35050763-A5F406A5-4126-4FA9-A9EC-941C2E864109Q35213142-84221DD9-C4EA-49DB-B8A2-FD6F48B6BEC1Q35706486-D78E8703-5E80-4EF6-9C27-CD7E9710BAF4Q35820476-94940482-B6C5-49F2-8D7F-CB7C72F22FAAQ35849079-DDF51E64-825C-4314-BB4C-48F1B35B4C5BQ35916658-0D7BED1D-6657-4102-8F14-E6A87171A766Q36007729-FCCDBE49-A920-409F-9D7A-0AAE87F102A6Q36023879-CEB599C5-6216-4518-8D49-A7C1DE64CB05Q36048177-8C1DB7B9-7D46-4338-BE6D-C41141BC5FD1Q36057973-41D524D5-6195-434C-A328-BC2FA8E9DFFFQ36186193-AFAA16F9-9D8A-4013-8226-D209FFC816A6Q36244744-1A5A5F0E-F833-4C62-B06E-E127AFB04E81Q36397684-156314BD-5ADE-448F-AB3A-713173928F79Q36503052-0801C627-30A9-412A-90B6-B92D8C1730EDQ36512866-E3C7BEE6-3DDD-4AB6-99D0-CAA588AA8053
P2860
Determinants of outcome in melanoma patients with cerebral metastases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Determinants of outcome in melanoma patients with cerebral metastases.
@en
type
label
Determinants of outcome in melanoma patients with cerebral metastases.
@en
prefLabel
Determinants of outcome in melanoma patients with cerebral metastases.
@en
P2093
P356
P1476
Determinants of outcome in melanoma patients with cerebral metastases.
@en
P2093
McCarthy WH
Petersen-Schaefer K
Shannon KF
P304
P356
10.1200/JCO.2004.08.140
P407
P577
2004-04-01T00:00:00Z